Summary
Inhibition of blood platelet aggregation by brinolase (fibrinolytic enzyme from Aspergillus oryzae) has been demonstrated with human platelets in vitro and with dog platelets in vivo and in vitro, using both ADP and collagen as aggregating stimuli. It is suggested that the optimal
inhibitory effects of brinolase occur indirectly through the generation of plasma
fibrinogen degradation products, without compromising platelet viability, rather than
by direct proteolysis of platelet structures.